HDAC6 and glioblastoma: For instance, a high-selective HDAC6 inhibitor, J22352, was reported to increased levels of immune-activating cytokines and the proliferation of CD8+ T cells by decreasing negative regulation of PD-L1, which made it possible to combine HDACis with immunotherapy to against GBM [197].